Table 3.

Several ongoing trials of ICIs combined with targeted therapy.

Trial	Phase	Treatment lines	Experimental arm	Enrolled population	Status
NCT03600701	II	≥2	Atezolizumab+combimetinib	Metastatic, Recurrent, or Refractory non-small cell lung cancer	Recruiting
NCT03299088	Ib	≥2	Pembrolizumab+trametinib	Stage IV non-small cell lung cancer with K-ras gene mutations	Active
NCT03225664	Ib/II	≥2	Pembrolizumab+trametinib	Recurrent non-small cell lung cancer	Active